Target-Based Drug Repositioning Using Large-Scale Chemical–Protein Interactome Data
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Drug repositioning, or the identification of new indications for known drugs, is a useful strategy for drug discovery. In this study, we developed novel computational methods to predict potential drug targets and new drug indications for systematic drug repositioning using large-scale chemical-protein interactome data. We explored the target space of drugs (including primary targets and off-targets) based on chemical structure similarity and phenotypic effect similarity by making optimal use of millions of compound-protein interactions. On the basis of the target profiles of drugs, we constructed statistical models to predict new drug indications for a wide range of diseases with various molecular features. The proposed method outperformed previous methods in terms of interpretability, applicability, and accuracy. Finally, we conducted a comprehensive prediction of the drug-target-disease association network for 8270 drugs and 1401 diseases and showed biologically meaningful examples of newly predicted drug targets and drug indications. The predictive model is useful to understand the mechanisms of the predicted drug indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Drug repositioning: a machine-learning approach through data integration
Napolitano, F., Zhao, Y., Moreira, V. M., Tagliaferri, R., Kere, J., D’Amato, M., & Greco, D. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-30 · Cited by 349
Luo, H., Chen, J., Shi, L., Mikailov, M., Zhu, H., Wang, K., He, L., & Yang, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr299 · Cited by 206
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
Samrao, A., Berry, T. M., Goreshi, R., & Simpson, E. L. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.812 · Cited by 166
Cited by
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Rifaioglu, A. S., Atas, H., Martin, M. J., Cetin-Atalay, R., Atalay, V., & Doğan, T. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby061 · Cited by 529
On the Integration of In Silico Drug Design Methods for Drug Repurposing
March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., & Rastelli, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00298 · Cited by 235
“On different grounds, predictive models built upon disease feature descriptors, large-scale drug–target and target–disease associations showed performance improvements in predicting new drug–disease links (Iwata et al., 2015; Sawada et al., 2015).”
BackgroundWang, R., Li, S., Cheng, L., Wong, M. H., & Leung, K. S. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3283-6 · Cited by 37
Formalizing drug indications on the road to therapeutic intent
Nelson, S. J., Oprea, T. I., Ursu, O., Bologa, C. G., Zaveri, A., Holmes, J., Yang, J. J., Mathias, S. L., Mani, S., Tuttle, M. S., et al. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx064 · Cited by 9
Metadata
- Authors
- Sawada, R., Iwata, H., Mizutani, S., & Yamanishi, Y.
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-12-01
- Volume
- 55
- Issue
- 12
- Pages
- 2717-2730
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2210241103
- Cited by
- 69
- References
- 13
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.